Unimed Pharmaceutical: Subsidiary Shanghai Unimed plans to increase its capital by 45 million yuan to acquire a 51% stake in Gu Kang Pharmaceutical.

Medical Announcement, the company's wholly-owned subsidiary Shanghai Weiming intends to increase its capital by 45 million yuan to Guangkang Pharmaceutical, obtaining 51% of its equity. After the capital increase is completed, Guangkang Pharmaceutical will become a subsidiary controlled by Shanghai Weiming. The capital increase price is based on the audited shareholder's equity value of Guangkang Pharmaceutical as of April 30, 2025, and has been determined through negotiation. This transaction does not constitute a related party transaction or a major asset reorganization, and has been approved by the company's sixth session of the board of directors at the second meeting, and can be exempted from the approval of the shareholders' meeting. This capital increase aims to improve the layout of the pharmaceutical industry chain, integrate high-quality internal and external resources, enhance the company's core competitiveness and industry comprehensive competitive advantage.